Altamira Therapeutics Ltd. reports developments around peptide-based nanoparticle technologies for RNA delivery to extrahepatic tissues. Company updates focus on the OligoPhore™ and SemaPhore™ platforms, preclinical siRNA programs including AM-401 for KRAS-driven cancer and AM-411 for rheumatoid arthritis, and the use of the delivery technology across RNA modalities.
Recurring news also covers Bentrio® nasal spray licensing and distribution through Altamira Medica, financing transactions involving common shares and warrants, interim financial results, business-update calls, and the company’s completed transition from Nasdaq trading to the OTCQB market under the CYTOF ticker.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.